Universal Beteiligungs und Servicegesellschaft mbH Purchases New Shares in Omnicell, Inc. (NASDAQ:OMCL)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 59,284 shares of the company's stock, valued at approximately $2,073,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.13% of Omnicell at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Johnson Financial Group Inc. bought a new position in shares of Omnicell during the 4th quarter valued at $37,000. Headlands Technologies LLC acquired a new position in Omnicell during the fourth quarter worth $53,000. Huntington National Bank increased its position in Omnicell by 236.4% during the fourth quarter. Huntington National Bank now owns 1,359 shares of the company's stock worth $61,000 after buying an additional 955 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in Omnicell during the fourth quarter valued at about $101,000. Finally, Corton Capital Inc. acquired a new stake in shares of Omnicell in the fourth quarter worth about $208,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Trading Down 4.0%

OMCL traded down $1.25 during trading on Friday, reaching $29.76. 742,476 shares of the company's stock were exchanged, compared to its average volume of 500,803. The company's fifty day moving average price is $29.27 and its 200-day moving average price is $33.11. The firm has a market capitalization of $1.39 billion, a PE ratio of 59.52, a P/E/G ratio of 8.69 and a beta of 0.77. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.74. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.23 and a current ratio of 1.42.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. The business had revenue of $290.56 million for the quarter, compared to the consensus estimate of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. Omnicell's revenue for the quarter was up 5.0% on a year-over-year basis. During the same period last year, the company posted $0.51 EPS. As a group, equities analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Wells Fargo & Company upped their price objective on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a report on Monday, July 21st. Benchmark cut their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Wall Street Zen raised Omnicell from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 12th. Bank of America lifted their price objective on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, May 23rd. Finally, Piper Sandler restated an "overweight" rating on shares of Omnicell in a research note on Friday, May 23rd. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $45.33.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.